FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals
The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly.
Company
Teva
Asset
Macitentan
Indication
Cardiology / Pulmonary Arterial Hypertension
Status
Approved
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly.
Why it matters
The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly.
What changed
Regulatory Approval
Analysis
Teva Pharmaceuticals has received approval for its Abbreviated New Drug Application (ANDA211187) for Macitentan.
The FDA's approval of Teva's ANDA for Macitentan introduces a new competitor in the pulmonary arterial hypertension market, which could disrupt pricing and market share for existing therapies. Pharma strategy teams must evaluate the implications for their portfolios and adjust strategies accordingly.
Monitor market uptake of Teva's Macitentan and any competitive responses from other manufacturers.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.